Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693613 | 1.00 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL6687832 | 0.86 | KDM4E (0.71) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL23710624 | 0.85 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL29471286 | 0.85 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL3660398 | 0.85 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL1494485 | 0.85 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL1494490 | 0.85 | KDM4E (0.69) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL17203129 | 0.82 | LMNA (0.60) | KDM4EPKMLMNATP53ADORA2A | |
| SCHEMBL29086896 | 0.82 | LMNA (0.53) | KDM4EPKMLMNATP53ADORA3 | |
| SCHEMBL29997464 | 0.82 | KDM4E (1.00) | KDM4EPKMLMNATP53ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949521-B2 | Therapeutic azide compounds | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20010036930-A1 | Therapeutic azide compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036930-A1 | Therapeutic azide compounds | ADA, ADK, DCK | KDM4E 1361/4885PKM 1420/4885LMNA 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.